children
age
month
yr
admit
depart
pediatr
turku
univers
hospit
septemb
may
acut
wheez
consid
studi
fig
method
describ
detail
earlier
exclus
criteria
system
corticosteroid
treatment
preced
wk
chronic
diseas
asthma
allergi
sever
wheez
necessit
intens
care
unit
treatment
previou
particip
studi
analysi
also
exclud
children
less
two
previou
wheez
attack
want
focu
recurr
wheez
addit
children
age
yr
exclud
narrow
age
distribut
previou
report
want
focu
children
atopi
defin
posit
immunoglobulin
e
antibodi
common
allergen
asthma
diagnos
fulfil
criteria
suggest
nation
heart
lung
blood
institut
usa
studi
protocol
approv
ethic
committe
turku
univers
hospit
written
inform
consent
obtain
parent
commenc
studi
need
hospit
decid
independ
studi
physician
emerg
room
ward
elig
children
randomli
assign
fashion
receiv
either
oral
prednisolon
first
dose
mgkg
mgkgd
three
divid
dose
day
maximum
dose
mgd
mg
tablet
leira
finland
placebo
inform
consent
obtain
patient
receiv
nebul
salbutamol
mgkg
maximum
singl
dose
mg
h
interv
first
h
h
interv
hospit
discharg
use
demand
hospit
patient
receiv
antibiot
n
nebul
racem
epinephrin
n
demand
medic
use
studi
physician
tj
pl
examin
patient
studi
entri
twice
daili
thereaft
hospit
stay
score
respiratori
symptom
child
discharg
guardian
record
child
symptom
diari
wk
follow
visit
month
parent
contact
phone
record
relaps
necessit
visit
physician
hospit
primari
endpoint
time
readi
discharg
defin
durat
respiratori
symptom
score
hospit
stay
respiratori
symptom
score
assess
everi
h
hospit
sum
score
degre
dyspnea
none
mild
moder
sever
type
breath
normal
use
stomach
muscl
use
intercost
muscl
nasal
flare
sever
auscultatori
find
wheez
none
expiratori
inspiratori
expiratori
audibl
without
stethoscop
assess
expiratori
inspiratori
time
estim
h
use
last
period
hospit
assess
ie
period
patient
becam
readi
discharg
secondari
endpoint
oxygen
satur
exhal
nitric
oxid
hospit
stay
wheez
cough
wk
discharg
impuls
oscillometri
bronchodil
wk
discharg
blood
eosinophil
count
discharg
wk
later
readmiss
clinic
hospit
recurr
wheez
period
discharg
admiss
nasopharyng
aspir
obtain
viral
analys
perform
rhinoviru
enterovirus
rsv
adenoviru
influenza
b
virus
parainfluenza
viru
type
coronaviru
strain
human
metapneumoviru
blood
sampl
eosinophil
analys
collect
entri
describ
analyz
accord
standard
clinic
routin
central
laboratori
turku
univers
hospit
turku
finland
exhal
success
collect
tidal
breath
offlin
collect
procedur
children
children
picornaviru
viru
infect
entri
accord
recommend
american
thorac
societi
random
ward
analyz
depart
clinic
physiolog
turku
univers
hospit
siever
nitric
oxid
analyz
siever
instrument
inc
boulder
co
usa
tripl
measur
respiratori
resist
rr
hz
perform
accord
normal
clinic
protocol
hospit
master
screen
io
erich
jaeger
gmbh
germani
measur
repeat
inhal
salbutamol
allow
detect
h
differ
half
averag
durat
stay
hospit
time
readi
discharg
group
placebo
group
estim
standard
deviat
h
maintain
alpha
error
beta
error
requir
size
sampl
children
treatment
group
normal
data
distribut
test
use
test
u
test
use
continu
variabl
categor
data
analyz
use
test
fischer
exact
test
efficaci
prednisolon
analyz
use
multivari
regress
analysi
gener
linear
model
backward
stepwis
elimin
model
use
neg
binomin
distribut
model
includ
studi
drug
age
atop
diseas
blood
eosinophil
count
entri
durat
preced
respiratori
symptom
viral
etiolog
picornavirus
rsv
antibiot
treatment
ie
variabl
baselin
differ
found
prednisolon
placebo
group
picornaviru
group
interpret
gener
linear
model
carri
use
concept
risk
ratio
rr
mean
much
risk
chang
independ
variabl
continu
chang
one
unit
categor
explanatori
variabl
rr
tell
great
risk
one
group
compar
anoth
group
interact
studi
drug
picornaviru
rhinoviru
enteroviru
posit
blood
eosinophil
count
entri
presenc
atopi
age
sever
symptom
also
test
ie
one
interact
model
eg
drug
picornaviru
interact
term
model
refer
estim
differ
drug
effect
picornaviru
group
furthermor
estim
drug
effect
certain
patient
group
eg
picornaviru
group
contrast
estim
formul
test
effect
drug
group
effect
prednisolon
oxygen
satur
exhal
nitric
oxid
first
h
hospit
stay
test
h
interv
use
repeat
measur
analysi
varianc
statist
signific
establish
p
valu
lower
statist
analys
carri
use
sasstat
r
softwar
version
sa
system
window
sa
institut
inc
cari
nc
usa
studi
period
children
hospit
random
receiv
prednisolon
placebo
fig
random
children
children
accept
analysi
includ
children
month
yr
old
wheez
episod
confirm
respiratori
viral
infect
one
hospit
children
complet
hospit
enteroviru
detect
case
rhinoviru
case
enteroviru
case
rsv
case
adenoviru
case
parainfluenza
viru
type
case
influenza
b
viru
case
coronaviru
case
metapneumoviru
case
mix
viral
infect
detect
case
children
children
month
old
children
month
old
children
month
yr
old
thirti
children
atop
children
asthma
children
posit
respiratori
picornaviru
ie
rhinoviru
enteroviru
often
atop
picornaviru
group
vs
viru
group
vs
p
often
sensit
aeroallergen
respect
vs
p
larger
number
blood
eosinophil
entri
studi
respect
mean
sd
vs
p
posit
virus
longer
durat
preced
respiratori
symptom
respect
mean
sd
vs
day
p
antibiot
treatment
respect
vs
p
detect
rsv
respect
vs
p
common
viru
group
picornaviru
group
otherwis
differ
found
viru
group
variabl
mention
data
shown
differ
viru
group
baselin
valu
treatment
group
compar
found
children
prednisolon
group
younger
p
placebo
group
tabl
otherwis
differ
record
baselin
characterist
prednisolon
group
placebo
group
children
success
impuls
oscillometri
differ
age
found
treatment
group
prednisolon
vs
placebo
mean
vs
yr
p
univari
regress
analysi
studi
drug
associ
primari
endpoint
time
readi
discharg
tabl
howev
signific
interact
studi
drug
age
picornaviru
infect
found
main
endpoint
secondari
endpoint
prednisolon
decreas
blood
eosinophil
count
discharg
patient
signific
interact
studi
drug
rhinoviru
infect
found
durat
symptom
discharg
multivari
regress
analysi
prednisolon
significantli
decreas
primari
endpoint
time
readi
discharg
prednisolon
vs
placebo
median
vs
h
p
final
model
includ
studi
drug
antibiot
treatment
picornaviru
infect
tabl
howev
prednisolon
decreas
time
readi
discharg
children
respiratori
picornaviru
infect
respect
vs
h
picornaviru
group
vs
h
group
p
interact
final
model
includ
studi
drug
picornaviru
infect
studi
drug
picornaviru
infect
picornaviru
group
rr
ci
p
group
rr
ci
p
specif
children
enteroviru
infect
respect
vs
h
enteroviru
group
vs
h
group
p
interact
final
model
includ
studi
drug
enteroviru
infect
picornaviru
infect
antibiot
treatment
studi
drug
enteroviru
infect
enteroviru
group
rr
ci
p
group
rr
ci
p
secondari
endpoint
prednisolon
decreas
durat
symptom
children
multivari
model
tabl
children
prednisolon
decreas
durat
cough
prednisolon
vs
placebo
median
vs
day
rhinoviru
group
vs
day
group
p
interact
final
model
includ
studi
drug
rhinoviru
infect
studi
drug
rhinoviru
infect
rhinoviru
group
rr
ci
p
group
rr
ci
p
dyspnea
respect
vs
day
rhinoviru
group
vs
day
group
p
interact
final
model
includ
studi
drug
rhinoviru
infect
age
studi
drug
rhinoviru
infect
rhinoviru
group
rr
ci
p
group
rr
ci
p
prednisolon
also
decreas
blood
eosinophil
discharg
children
respect
vs
rr
ci
p
final
model
includ
studi
drug
effect
longer
present
wk
discharg
signific
differ
interact
found
data
partli
shown
tabl
efficaci
prednisolon
tend
associ
atopi
increas
blood
eosinophil
count
atop
children
prednisolon
tend
decreas
durat
cough
prednisolon
vs
placebo
median
interquartil
rang
vs
day
atop
vs
day
children
p
interact
final
model
includ
studi
drug
atopi
studi
drug
atopi
dyspnea
respect
vs
day
atop
children
vs
day
children
p
interact
final
model
includ
studi
drug
atopi
age
studi
drug
atopi
children
increas
blood
eosinophil
count
prednisolon
also
tend
decreas
durat
cough
respect
median
vs
day
blood
eosinophil
vs
day
blood
eosinophil
p
interact
final
model
includ
studi
drug
blood
eosinophil
studi
drug
blood
eosinophil
median
use
point
blood
eosinophil
differ
found
oxygen
satur
exhal
nitric
oxid
measur
hospit
stay
treatment
group
respect
repeat
measur
analysi
varianc
p
data
shown
neither
differ
found
impuls
oscillometri
measur
wk
discharg
treatment
group
prednisolon
vs
placebo
median
interquartil
rang
vs
p
differ
mg
salbutamol
inhal
vs
p
prednisolon
treatment
well
toler
clinic
signific
advers
effect
occur
abl
demonstr
benefit
prednisolon
treatment
standard
dosag
children
hospit
recurr
wheez
acut
asthma
clinic
endpoint
howev
demonstr
efficaci
treatment
primari
outcom
time
readi
discharg
respiratori
episod
wheez
also
found
prednisolon
reduc
durat
cough
dyspnea
children
prednisolon
effect
decreas
blood
eosinophil
count
discharg
patient
effect
lost
within
wk
efficaci
studi
focus
natur
respiratori
picornaviru
infect
difficult
design
conduct
delay
viral
diagnosi
necessit
inclus
larg
number
patient
subsequ
analysi
result
although
efficaci
studi
avail
children
suffer
recurr
wheez
asthma
efficaci
prednisolon
wheez
expect
basi
high
detect
rate
respiratori
picornavirus
acut
childhood
asthma
separ
studi
show
efficaci
system
corticosteroid
patient
group
howev
surpris
find
prednisolon
also
decreas
durat
hospit
picornaviru
affect
children
previou
studi
pediatr
asthma
difficulti
demonstr
recent
studi
shown
efficaci
discharg
rate
first
outpati
ward
improv
clinic
sever
score
number
relaps
month
discharg
durat
hospit
rapid
resolut
wheez
median
h
children
make
difficult
demonstr
decreas
hospit
time
neg
clinic
outcom
patient
may
thu
differ
viral
etiolog
ill
broader
scope
associ
certain
host
characterist
picornaviru
infect
evid
certain
children
suffer
earli
wheez
rsv
infect
may
benefit
system
corticosteroid
daugbjerg
et
al
studi
wheez
children
age
month
found
shorter
durat
hospit
prednisolon
placebo
group
children
goebel
et
al
studi
wheezer
age
less
yr
show
lower
symptom
score
prednisolon
group
placebo
group
children
schuh
et
al
show
mark
effect
singl
dose
dexamethason
wheezer
age
wk
month
emerg
room
set
half
number
children
recent
finnish
studi
show
shorter
hospit
stay
shorter
durat
symptom
wheez
children
age
month
treat
prednisolon
although
viral
diagnost
use
studi
mani
children
older
typic
infect
rsv
children
clearli
benefit
corticosteroid
rhinoviru
detect
enterovirus
case
bronchiol
case
earlier
studi
support
view
system
corticosteroid
may
effect
respiratori
children
final
demonstr
earlier
report
standard
dose
prednisolon
reduc
relaps
period
first
second
episod
wheez
associ
rhinoviru
infect
andor
blood
eosinophil
rsv
infect
children
age
month
previou
studi
earli
wheez
agreement
current
report
recurr
wheez
benefici
effect
system
corticosteroid
acut
childhood
wheez
induc
respiratori
picornavirus
support
studi
experiment
rhinoviru
infect
adult
studi
system
inhal
nasal
corticosteroid
administ
adult
atop
adult
mild
asthma
clearli
reduc
symptom
airway
respons
argu
experiment
infect
adult
mild
asthma
compar
natur
viral
infect
children
especi
case
necessit
hospit
children
suscept
wheez
may
present
case
viral
ill
instead
case
may
reveal
children
underli
immunolog
anomali
predispos
sever
outcom
rhinoviru
infect
specul
markedli
elev
baselin
eosinophil
count
higher
preval
atopi
found
children
compar
children
affect
virus
may
also
increas
suscept
sever
diseas
howev
signific
interact
studi
drug
blood
eosinophil
count
entri
atopi
age
current
studi
system
corticosteroid
effect
decreas
inflammatori
marker
includ
blood
eosinophil
acut
asthma
report
concern
durat
effect
limit
asthmat
children
eosinopen
effect
report
last
least
day
discontinu
treatment
prednisolon
asthmat
adult
blood
eosinophil
return
baselin
level
wk
treatment
prednisolon
studi
differ
eosinophil
level
found
wk
prednisolon
treatment
appear
eosinopen
effect
cours
prednisolon
lost
within
wk
agreement
previou
report
earli
wheez
sever
limit
studi
must
taken
account
result
difficulti
design
studi
children
analys
carri
post
hoc
power
calcul
base
previou
data
efficaci
avail
final
sampl
size
quit
small
could
account
neg
find
eg
efficaci
associ
atopi
increas
blood
eosinophil
despit
intens
search
detect
respiratori
picornaviru
infect
low
like
reason
prolong
time
readi
discharg
children
receiv
prednisolon
compar
placebo
reliabl
posit
pcr
test
detect
activ
viral
infect
may
question
previous
shown
wheez
patient
case
posit
picornaviru
pcr
markedli
decreas
within
wk
disappear
within
wk
acut
wheez
suggest
pcr
posit
relat
acut
infect
current
studi
viral
load
assess
balanc
random
lost
exclus
mani
subject
analysi
note
result
come
variou
subgroup
analys
secondari
outcom
final
studi
hospit
children
receiv
abund
bronchodil
medic
exclud
children
requir
intens
care
strength
studi
includ
care
record
risk
factor
detail
viral
diagnost
prospect
conclus
find
support
view
system
corticosteroid
dosag
use
effect
children
suffer
episod
recurr
wheez
asthma
patient
prednisolon
treatment
reduc
sever
durat
diseas
prospect
design
clinic
trial
appropri
power
need
test
hypothesi
prednisolon
reduc
symptom
rhinoviru
wheez
children
